Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma

ClinicalTrials.gov Identifier: NCT03876028

Novartis Reference Number: CCTL019L12101C

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.

Condition 
Diffuse Large B-cell Lymphoma
Phase 
Phase 1
Overall status 
Active, not recruiting
Enrollment count 
10 participants
Start date 
Jun 11, 2019
Completion date 
Aug 08, 2022
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Biological
Tisagenlecleucel
Infusion
Drug
Ibrutinib
Oral (tablets or capsules)

Eligibility Criteria

Inclusion Criteria:

Confirmed DLBCL as per the local histopathological assessment.
Relapsed or refractory disease having received 2 or more lines of systemic therapy, including anti-CD20 and anthracycline based chemotherapy, and either having progressed after (or relapsed after) ASCT, or being ineligible for or not consenting to ASCT.
Measurable disease at time of enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening.
Adequate renal, liver, and bone marrow, organ function, and minimum level of pulmonary reserve.

Exclusion Criteria:

Patients with Richter's transformation, Burkitt's lymphoma, and primary DLBCL of the CNS.
Prior anti-CD19 directed therapy.
Prior gene therapy.
Prior adoptive T cell therapy.
Prior ibrutinib therapy within the 30 days prior to screening.
Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was > 4 weeks before enrollment.
Prior allogeneic HSCT
. Significant cardiac abnormality including history of myocardial infarction within 6 months prior to screening as detailed in the study protocol.

Other eligibility criteria may apply.

Study Locations

United States
H Lee Moffitt Cancer Center and Research Institute
-
Tampa, 33612
Florida
United States
University of Pennsylvania, Abramson Cancer Center
-
Philadelphia, 19104
Pennsylvania
United States

Have a question?

Call 1-999-669-6682 or email [email protected]